SOURCE: PharmaRoth Labs, Inc.

February 23, 2016 08:30 ET

PharmaRoth Labs, Inc. Provides Update on Registration Process to Market and Distribute Sucanon in India

LAS VEGAS, NV--(Marketwired - Feb 23, 2016) -  PharmaRoth Labs, Inc. (OTC PINK: ROTH), the exclusive producer, marketer, and distributor of Sucanon®, an oral Type-II Diabetes treatment, is pleased to provide this update regarding the registration process in India. The Company previously announced the execution of a Distribution Agreement under which Sucanon® would be marketed and distributed as an Over the Counter (OTC). The Ministry of Health in India has approved all of the labeling and marketing information for the product container, allowing Sucanon®'s application to move forward to the clinical trial phase.

"We are very pleased with how smoothly the registration process has been going in India," commented Luis Lopez, CEO of PharmaRoth. "The Ministry's approval of the artwork design on the packaging allows us to move on to the next significant milestone: to submit the completed application for the registration and begin the 12-week clinical trial, which we plan to start soon."

India, by the nature of its immense population and the rate of Type-II Diabetes growth, is a very important market for PharmaRoth. According to the Australian Medical Journal, in the year 2000, India had the highest number of people afflicted with Type-II Diabetes; and according to predictions, up to 79.4 million people in India may be afflicted with diabetes mellitus by the year 2030.

"Our company has the ability to offer an effective OTC Type-II diabetes treatment with no side effects to a region of world where the disease is rampant, and we are proud to be able to provide Sucanon® to the people of India," Mr. Lopez concluded. 

About Sucanon®
Sucanon® is a diabetes oral treatment containing natural ingredient. In certain countries, it is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers." Pre-clinical and clinical studies have shown that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® is currently approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico and is distributed thought Mexico at various pharmacy chains.

For more information regarding Sucanon®, please visit

About PharmaRoth
PharmaRoth Labs, Inc. (OTC PINK: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

Forward Looking Statements: Statements in this document contain certain forward-looking Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of PharmaRoth Labs, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. PharmaRoth Labs, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors. There may be other factors not mentioned above that may cause actual results to differ materially from those projected in any forward-looking statement. We assume no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws.

Contact Information

  • For Investor Relations contact:

    Michael Irving
    Paramount Advisors, LLC
    (407) 878-5462